🇺🇸 Olmesartan/amlodipine in United States

82 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 82

Most-reported reactions

1. Fatigue — 14 reports (17.07%)
2. Drug Ineffective — 10 reports (12.2%)
3. Death — 8 reports (9.76%)
4. Malaise — 8 reports (9.76%)
5. Nausea — 8 reports (9.76%)
6. Weight Decreased — 8 reports (9.76%)
7. Diarrhoea — 7 reports (8.54%)
8. Dizziness — 7 reports (8.54%)
9. Abdominal Pain — 6 reports (7.32%)
10. Chest Pain — 6 reports (7.32%)

Source database →

Frequently asked questions

Is Olmesartan/amlodipine approved in United States?

Olmesartan/amlodipine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Olmesartan/amlodipine in United States?

Institut für Pharmakologie und Präventive Medizin is the originator. The local marketing authorisation holder may differ — check the official source linked above.